

Bonnet Gesamtliteratur

- Adejumo AC, Alliu S, Ajayi TO, Adejumo KL, Adegba OM, Onyeakusi NE, Akinjero AM, Durojaiye M, Bukong TN: Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study. *PLoS One* 2017; 12: e0176416.
- APA (American Psychiatric Association): *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5™)*. Washington, DC: APA 2013.
- Atzendorf J, Rauschert C, Seitz N-N, Lochbühler K, Kraus L: Gebrauch von Alkohol, Tabak, illegalen Drogen und Medikamenten. Schätzungen zu Konsum und substanzbezogenen Störungen in Deutschland. *Dtsch Ärztebl Int* 2019; 116: 577–584.
- Bonnet U, Specka M, Stratmann U, Ochwaldt R, Scherbaum N: Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum. *Drug Alcohol Depend* 2014; 143: 189–197.
- Bonnet U, Borda T, Scherbaum N, Specka M: Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification (Part II): Psychiatric complaints and their relation to delta-9-tetrahydrocannabinol and its metabolites in serum. *Drug Alcohol Depend* 2015; 155: 302–306.
- Bonnet U: Rauschzustände: Risiken und Nebenwirkungen. Im Focus: nicht-medizinisches Cannabis und synthetische Cannabinoide. *Suchttherapie* 2016; 17: 61–70.
- Bonnet U, Specka M, Scherbaum N: Häufiger Konsum von nicht-medizinischem Cannabis. Gesundheitliche Folgen und Wirkung der Entzugsbehandlung. *Dtsch Med Wochenschr* 2016; 141: 126–131.
- Bonnet U, Preuss UW: The cannabis withdrawal syndrome: current insights. *Subst Abuse Rehabil* 2017; 8: 9–37.
- Budney AJ, Novy PL, Hughes JR: Marijuana withdrawal among adults seeking treatment for marijuana dependence. *Addiction* 1999; 94: 1311–1322.
- Busner J, Targum SD: The Clinical Global Impression Scale: Applying a research tool in clinical practice. *Psychiatry (Edgemont)* 2007; 4: 28–37.
- BZgA (Bundeszentrale für gesundheitliche Aufklärung). Forschungsbericht Juni 2019. Der Cannabiskonsum Jugendlicher und junger Erwachsener in Deutschland: Ergebnisse des Alkoholsurveys 2018 und Trends Köln: BZgA, 2019. https://www.bzga.de/fileadmin/user_upload/PDF/studien/Alkoholsurvey_2018_Cannabis-Bericht.pdf
- Conner SN, Carter EB, Tuuli MG, Macones GA, Cahill AG: Maternal marijuana use and neonatal morbidity. *Am J Obstet Gynecol* 2015; 213: 422.e1–4.
- Cogle JR, Hakes JK, Macatee RJ, Chavarria J, Zvolensky MJ: Quality of life and risk of psychiatric disorders among regular users of alcohol, nicotine, and cannabis: An analysis of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). *J Psychiatr Res* 2015; 66–67: 135–141.
- Danielsson AK, Falkstedt D, Hemmingsson T, Allebeck P, Agardh E: Cannabis use among Swedish men in adolescence and the risk of adverse life course outcomes: results from a 20 year-follow-up study. *Addiction* 2015; 110: 1794–1802.
- Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M et al.: Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. *Lancet Psychiatry* 2015; 2: 233–238.
- Dilling H, Mombour W, Schmidt MH: *Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F). Diagnostische Kriterien für Forschung und Praxis*. Bern: Huber, 2004.
- Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, Bressan RA, Lacerda AL: Cannabis use before age 15 and subsequent executive functioning. *Br J Psychiatry* 2011; 198: 442–447.
- Franke G: *SCL-90-R. Die Symptomcheckliste von Derogatis – Deutsche Version – Manual*. 2. Aufl. Göttingen: Hogrefe, 2002.
- Freeman TP, Winstock AR: Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. *Psychol Med* 2015; 45: 3181–3189.
- Grotenhermen F, Leson G, Berghaus G, Drummer OH, Krüger HP, Longo M, Moskowitz H, Perrine B, Ramaekers JG, Smiley A, Tunbridge R: Developing limits for driving under cannabis. *Addiction* 2007; 102: 1910–1917.
- Hall W, Degenhardt L: The adverse health effects of chronic cannabis use. *Drug Test Anal*. 2014; 6: 39–45.
- Hancox RJ, Shin HH, Gray AR, Poulton R, Sears MR: Effects of quitting cannabis on respiratory symptoms. *Eur Respir J* 2015; 46: 80–87.
- Hartung B, Kaufenstein S, Ritz-Timme S, Daldrup T: Sudden unexpected death under acute influence of cannabis. *Forensic Sci Int* 2014; 237: e11–13.
- Holzbach R, Behrendt K, Maylath E, Küstner U, Schreyer D, von Berghes A, Fuchs E, Brack J, Steenblock R, Gabriel K, Haasen C, Thomasius R: Positionspapier zum stationären qualifizierten Entzug von Cannabispatienten. *Suchtmedizin* 2006; 8: 9–14.
- Huizink AC: Prenatal cannabis exposure and infant outcomes: overview of studies. *Prog Neuropsychopharmacol Biol Psychiatry* 2014; 52: 45–52.
- Hurd YL, Michaelides M, Miller ML, Jutras-Aswad D: Trajectory of adolescent cannabis use on addiction vulnerability. *Neuropharmacology* 2014; 76 Pt B: 416–424.
- Karila L, Roux P, Rolland B, Benyamina A, Reynaud M, Aubin HJ, Lançon C: Acute and long-term effects of cannabis use: a review. *Curr Pharm Des* 2014; 20: 4112–4118.
- McLaren J, Swift W, Dillon P, Allsop S: Cannabis potency and contamination: a review of the literature. *Addiction* 2008; 103: 1100–1109.
- Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE: Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc Natl Acad Sci USA* 2012; 109: E2657–2664.
- Muniyappa R, Sable S, Ouwerkerk R, Mari A, Gharib AM, Walter M, Courville A, Hall G, Chen KY, Volkow ND, Kunos G, Huestis MA, Skarulis MC: Metabolic effects of chronic cannabis smoking. *Diabetes Care* 2013; 36: 2415–2422.
- Oberlandesgericht Brandenburg, 2007. Fahrverbot und THC—Mindestgrenzwert. Az: 1 Ss (OWi) 291 B/06. Beschluss vom 30.03.2007, <http://verkehrsrechtsforum.de/urteilsdatenbank/fahrverbot/teil-1/fahrverbot-thc—mindestgrenzwert.htm>.

Ortiz-Medina MB, Perea M, Torales J, Ventriglio A, Vitrani G, Aguilar L, Roncero C: Cannabis consumption and psychosis or schizophrenia development. *Int J Soc Psychiatry* 2018; 64: 690–704.

Penner EA, Buettner H, Mittleman MA: The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. *Am J Med* 2013; 126: 583–589.

Raemakers JC, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G: Cognition and motor control as a function of Delta-9-THC concentration in serum and oral fluid: limits of impairment. *Drug Alcohol Depend* 2006; 85: 114–122.

Rodríguez-Castro CE, Alkhateeb H, Elfar A, Saifuddin F, Abbas A, Siddiqui T: Recurrent myopericarditis as a complication of Marijuana use. *Am J Case Rep* 2014, 15: 60–62.

Rooke SE, Norberg MM, Copeland J, Swift W: Health outcomes associated with long-term regular cannabis and tobacco smoking. *Addict Behav* 2013; 38: 2207–2213.

Salomonsen-Sautel S, Min SJ, Sakai JT, Thurstone C, Hopfer C: Trends in fatal motor vehicle crashes before and after marijuana commercialization in Colorado. *Drug Alcohol Depend* 2014; 140: 137–144.

Schneider M: Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. *Addict Biol* 2008; 13: 253–263.

Sexton M, Cuttler C, Mischley LK: A survey of cannabis acute effects and withdrawal symptoms: differential responses across user types and age. a survey of cannabis acute effects and withdrawal symptoms: differential responses across user types and age. *J Altern Complement Med* 2019; 25: 326–335.

Silins E, Horwood LJ, Patton GC, Fergusson DM, Olsson CA, Hutchinson DM, Spry E, Toumbourou JW, Degenhardt L, Swift W, Coffey C, Tait RJ, Letcher P, Copeland J, Mattick RP: Young adult sequelae of adolescent cannabis use: an integrative analysis. *Lancet Psychiatry* 2014; 4: 286–293.

Swift W, Wong A, Li KM, Arnold JC, McGregor IS: Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. *PLoS One* 2013; 8(7): e70052.

Tarantino G, Citro V, Finelli C: Recreational drugs: a new health hazard for patients with concomitant chronic liver diseases. *J Gastrointest Liver Dis* 2014; 23: 79–84.

Thomas G, Kloner RA, Rezkalla S: Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. *Am J Cardiol* 2014; 113: 187–190.

van Amsterdam J, Phillips L, Henderson G, Bell J, Bowden-Jones O, Hammersley R, Ramsey J, Taylor P, Dale-Perera A, Melichar J, van den Brink W, Nutt D: Ranking the harm of non-medically used prescription opioids in the UK. *Regul Toxicol Pharmacol* 2015; 73: 999–1004.

Winhusen T, Theobald J, Kaelber DC, Lewis D: Regular cannabis use, with and without tobacco co-use, is associated with respiratory disease. *Drug Alcohol Depend* 2019; 204: 107557.